宫颈上皮细胞FH/ROS联合检测在宫颈癌筛查中的临床应用价值

Clinical Application Value of FH/ROS Combined Test in Cervical Cancer Screening

摘要: 目的：探讨宫颈上皮细胞游离亚铁原卟啉/活性氧自由基(FH/ROS)联合检测在宫颈癌及癌前病变中的临床应用价值。方法：2019年3月至2019年6月遵义医科大学附属妇幼保健院(遵义市妇幼保健院)妇科接受宫颈癌筛查的女性患者360例，选取同时具有TCT检测及病理检查结果的300例，对其FH/ROS联合检测，以病理学诊断结果作为金标准，分析FH/ROS联合检测和TCT对宫颈癌与CIN检测的灵敏度、特异度、准确度。结果：上皮细胞FH/ROS联合检测阳性率高于TCT (P < 0.05)，其灵敏度、特异度、准确度分别是100%、85.7%、91.3%，TCT检测的灵敏度、特异度、准确度分别为82.05%、81.4%、85.3%。结论：FH/ROS联合检测作为宫颈癌筛查方法具有简便快速，检测成本较低，灵敏度较高等特点，值得临床推广应用。

Abstract: Objective: To investigate the clinical significance of free ferrous porphyrin/reactive oxygen free radical (FH/ROS) combined test in cervical cancer screening. Methods: A total of 300 women pathologically diagnosed with cervical intraepithelial neoplasia (CIN), cervical cancer and normal cervix were detected by FH/ROS combined test and thin-prep cytology test (TCT). The sensitivity, specificity and accuracy of TCT and FH/ROS combined test for cervical lesions were compared. Results: The positive rate of FH/ROS combined test was higher than TCT (P < 0.05), the sensitivity, specificity and accuracy of FH/ROS combined test were 100%, 85.7% and 91.3%, respectively, and the sensitivity, specificity and accuracy of TCT were 82.05%, 81.4% and 85.3% respectively. Conclusion: FH/ROS combined test has simple, fast, low-cost advantages and high sensitivity of detection, which is worthy to be used as clinical early warning detection technology in cervical cancer screening.